Compounds such as cannabidiol (CBD) and tetrahydrocannabinol (THC) have demonstrated promising potential in addressing inflammation due to their interaction with the body's endocannabinoid system. CBD, a non-psychoactive component of cannabis, possesses notable anti-inflammatory properties, which have been studied for their ability to reduce inflammation by influencing immune responses and suppressing inflammatory cytokines. On the other hand, THC, the psychoactive compound, also exhibits anti-inflammatory effects by interacting with cannabinoid receptors in the immune system, potentially modulating immune responses and dampening inflammation. Both cannabinoids have shown promise in preclinical and clinical studies for managing various inflammatory conditions, such as arthritis, multiple sclerosis, and inflammatory bowel diseases.